ArticleScientific reports2025
Combined cerebrospinal fluid sCD163, MMP-9, with serum NCAM1 protein levels for predicting the prognosis of patients with tuberculous meningitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic Roles of InlA, InlB and LLO in the Infection of Trigeminal Ganglion Neurons by Ovine-DerivedAnimals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Tuberculous meningitis (TBM) is the most serious type of tuberculosis infection, and there is a lack of accurate diagnostic targets for TBM. Therefore, it is of great clinical and public health significance to find a specific target for early diagnosis and prediction of the prognosis of TBM. From January 2021 to February 2024, 110 TBM patients and 122 patients with non-tumor, non-infectious headaches were admitted to Hunan Chest Hospital. To compare the two groups, cerebrospinal fluid (CSF) levels of sCD163 and MMP-9, as well as serum NCAM1 protein levels, were detected by ELISA. Multivariate logistic regression analysis or Spearman analysis was then performed to investigate the correlation between these protein levels and the MRC (Medical Research Council) stage or the short-term prognosis in TBM patients. sCD163 and MMP-9 were elevated in the CSF of TBM patients compared to controls. Oppositely, the protein levels of serum NCAM1 was decreased. The levels of CSF sCD163, MMP-9 and serum NCAM1 are associated with MRC stage and short-term prognosis of TBM patients, and the combined CSF sCD163, MMP-9 and serum NCAM1 have the best value in predicting the short-term prognosis of TBM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.